MMAF sodium (Monomethylauristatin F sodium) 是一种有效的微管蛋白聚合 (tubulin polymerization) 抑制剂，用作抗肿瘤药物。MMAF sodium (Monomethylauristatin F sodium) 广泛用作抗体-药物偶联物 (ADCs) 的细胞毒性成分，如Vorsetuzumab mafodotin 和 SGN-CD19A。
货号:ajcx14748
CAS:1799706-65-2
分子式:C39H64N5NaO8
分子量：753.94
溶解度:DMSO: ≥ 200 mg/mL (265.27 mM)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A[1][2][3].

MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC50s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay[4].

[1]. Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70. [2]. Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4. [3]. Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics. [4]. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.